This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Repair a broken budget by reevaluating priorities, trimming nonessential costs, and implementing sustainable changes to regain financial balance.
10,068 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
NVIDIA CEO Jensen Huang predicts AI agents will infiltrate every function in every company, signaling a new phase for...
In a market rotating away from fast-growing tech, three dividend aristocrat stocks that have raised payouts for decad...
CF Industries has surged this year on supply constraints and cost advantages, yet a DOJ probe adds regulatory risk th...
Novo Nordisk has drifted toward a five-year low, raising questions about value vs. risk. This guide breaks down the f...
American Express has fallen notably in 2026, prompting questions about whether the drop makes it a bargain. This arti...
Navitas Semiconductor is pursuing an AI data-center power strategy built around 800V architecture. This move could re...
Starting with $1,000 doesn’t require luck or timing. This guide identifies the smartest Vanguard option for a straigh...
The U.S. Department of Housing and Urban Development has opened a Fair Housing Act investigation into Washington stat...
In 2026, breadth returns as equal-weight ETFs beat the S&P 500, nudging investors toward diversified exposure. Here a...
Braze stock surged today as the marketing-tech player highlighted AI-driven growth and stronger customer engagement m...
As collections on federal student loans restart, Gen Z is bearing the cost with rising delinquencies and falling cred...